StockTipsArenaBeta

BUY Aurobindo Pharma — Bank of America

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byBank of AmericaHorizon: NA (inferred 1 year)7 Aug 2026via CNBC Awaaz.

Entry₹1,625.4Inferred
Target₹1,800
Total upside +10.74% (call closed)
Stop lossNot given
Exit₹1,8006 Nov 2026, 9:16 am
Target hit+10.74%0.00%upside left
Follow Bank of America for new callsGet alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 9 active Long-term calls on AUROPHARMASee 273 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 6 Nov 2026
54 supporting18 neutral7 opposing
Supports the BUY call (54)

5 other SEBI-registered advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · same horizon·6 Nov · today

Aurobindo Pharma Q2 profit rises 33%, beats estimates; declares ₹7 interim dividend

NewsCnbc-Tv18·4 Nov · yesterday

(opens in new tab)

Aurobindo Pharma Q2 Results: Profit Rises 33%, Shareholders To Get Dividend By Nov 20

NewsNdtv-Profit·4 Nov · yesterday

(opens in new tab)

Aurobindo Pharma reported Q2 FY27 consolidated revenue of INR 10,263 Cr (up 24% YoY) and net profit of INR 1,124 Cr (up 32.5% YoY). The company also declared an interim dividend of INR 7.0 per share.

NSE · Press Release·4 Nov · yesterday

(opens in new tab)

Aurobindo Pharma reported strong Q2 FY27 results with revenue of INR 10,263 Cr (up 24% YoY) and net profit of INR 1,124 Cr (up 32.5% YoY). The company also declared an interim dividend of INR 7.0 per

BSE · Company Update·4 Nov · yesterday

(opens in new tab)
Neutral / worth noting (18)

The company transferred ownership of its Russian subsidiary, Auro Pharma LLC, between two of its wholly owned subsidiaries.

BSE · Company Update·4 Nov · yesterday

(opens in new tab)

Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·4 Nov · yesterday

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3w ago

(opens in new tab)
Weighs against the BUY call (7)

2 other SEBI-registered advisors have active long-term SELL calls on this stock

Advisor consensus · same horizon·6 Aug · 3mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Bank of America

Every call and its outcome